Goal is to improve patient health outcomes for organ and tissue
MARKHAM, ON, July 3, 2013 /CNW/ - Astellas Pharma Canada, Inc. has announced a new partnership with the
recently launched Canadian National Transplant Research Program
(CNTRP), a novel research initiative that brings a collaborative and
transdisciplinary approach to advancing research and patient care in
the field of transplant.
Astellas has pledged $1 Million over a period of five years to support
Canadian investigators in the transplant field as they work to address
barriers to tissue and organ donation, with the ultimate goal of
improving long-term outcomes and quality of life for transplant
The program is led by Dr. Lori West at the Alberta Transplant Institute,
University of Alberta, and Dr. Marie-Josée Hébert at the Université de
Montréal. It brings together 105 investigators and 86 collaborators
from 13 different universities and research centres across Canada.
"By bringing the transplant research community together with industry,
we will be able to investigate barriers to improve the availability of
transplants for all patients who need them, to improve the safety of
transplants so we can have better long-term results and fewer
complications, as well as to improve the efficacy of transplants so we
can improve the quality of life of patients who have been
transplanted," says Dr. Lori West, Director of the CNTRP and Professor
of Pediatrics, Surgery and Immunology at the University of Alberta.
"Industry engagement with the university-based academic researchers of
the CNTRP will be exceedingly helpful in guiding subsequent innovation
by engaging basic science and clinical researchers in the continuum of
discovery. Stronger bridging with industry will accelerate health
outcome improvements and create an environment for innovation, on which
the CNTRP will build commercial partnerships towards better health for
The program has the potential to have a transformative effect on the
field of transplantation. The hope is not only to increase scientific
knowledge to improve current healthcare practices, but also to drive
further research that will ultimately translate into novel treatments
and enhanced donation policies for the future. The CNTRP is the first
program in the world to unite and integrate the solid organ transplant,
bone marrow transplant and the donation and critical care research
communities together in a groundbreaking national research endeavour.1
"Astellas has a proud history of supporting the Canadian transplant
community," says Michael Tremblay, President, Astellas Pharma Canada,
Inc. "We are pleased to be able to provide additional support for key
research activities that will ultimately lead to better outcomes for
transplant patients here in Canada, and beyond."
About the Canadian National Transplant Research Program (CNTRP)
The Canadian National Transplant Research Program (CNTRP) is a national
initiative designed to increase organ and tissue donation in Canada and
enhance the survival and quality of life of Canadians who receive
transplants. The research goals of the CNTRP:
Increase the availability of transplants
Extend the longevity of grafts
Improve the long-term survival and quality of life of transplant
Develop and enhance the pool of researchers and clinicians in the field
Integrate and coordinate transplantation research nationwide
More information about CNTRP can be found at www.cntrp.ca.
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a
Canadian affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a
pharmaceutical company dedicated to improving the health of people
around the world through the provision of innovative and reliable
pharmaceutical products. The organization is committed to becoming a
global category leader in focused areas by combining outstanding R&D
and marketing capabilities. In Canada, Astellas has an intense
commercial focus on five therapeutic areas - Urology, Immunology,
Infectious Disease, Dermatology and Oncology.
For more information about Astellas Pharma Canada, Inc., please visit
the corporate website: www.astellas.ca
1 Harper Government supports Canadian National Transplant Research Program. Press release, dated April 22, 2013.
SOURCE: Astellas Pharma Canada, Inc.
For further information:
Astellas Pharma Canada, Inc.
Dr. Lori West
Director, Canadian National Transplant Research Program